Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  CanSino Biologics Inc.    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 08/10
222.2 HKD   -7.80%
10:34aCanSino to start Phase III trial of COVID-19 vaccine in Saudi
RE
08/07AstraZeneca Sets Deal in China Market -- WSJ
DJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

CanSino coronavirus vaccine shows immune response in human trial

share with twitter share with LinkedIn share with facebook
07/20/2020 | 10:13am EDT

July 20 (Reuters) - A vaccine against the coronavirus developed by CanSino Biologics Inc and China's military research unit appears to be safe and induced immune responses in most subjects in a closely-watched mid-stage study, researchers said on Monday.

The CanSino candidate, Ad5-nCOV, which was tested in 508 subjects, is one of a handful of vaccines that have shown some promise in early human testing prior to much larger trials to demonstrate efficacy. Others also gearing up for such pivotal vaccine trials include Moderna Inc, BioNTech SE in partnership with Pfizer Inc.

Data from a combined early/midstage trial of a vaccine candidate being developed by researchers at the University of Oxford and AstraZeneca was also released on Monday.

A safe and effective vaccine against the novel coronavirus is seen as essential to ending a pandemic that is still raging and has claimed more than 600,000 lives worldwide.

CanSino's vaccine uses a modified common cold virus to carry genetic material from the new coronavirus into the human body, a method also used by the Oxford/AstraZeneca vaccine.

Both vaccines elicited antibody and T-cell immune responses and neither prompted any serious side effects. T-cells are an important component of the immune system's attack against foreign invaders, such as viruses.

Results of both trials were released in the medical journal the Lancet.

Both studies augur well for the large Phase III trials, where the vaccines will be tested on thousands of subjects to assess their efficacy and safety, Naor Bar-Zeev and William Moss, from the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health, said in an accompanying editorial.

"Overall, the results of both trials are broadly similar and promising," they said.

Separately, BioNTech and Pfizer said data from an early-stage trial of their experimental coronavirus vaccine showed that it prompted an immune response and was well-tolerated, similar to results seen in prior early test.

CanSino's vaccine received the greenlight to be used by China's military despite not yet undergoing the type of large-scale testing needed to prove its ability to prevent infection.

Lilly Asia Ventures, backed by U.S. drugmaker Eli Lilly and Co, is CanSino's top shareholder, according to Refinitiv data. Lilly shares were up about 0.6%.

Chinese researchers in an earlier peer-reviewed paper noted that the immune responses elicited by the vaccine might be undermined if the inoculated person has already developed high-level adenovirus immunity from a previous infection.

That limitation cropped up again with Monday's results. Study authors said increasing age and high pre-existing adenovirus immunity significantly reduced immune responses to the vaccine.

Pre-existing immunity to the type of virus used to deliver the vaccine "is considered to be the biggest obstacle for the candidate ... COVID-19 vaccine to overcome," study authors said.

In some participants with adenovirus immunity, one injection might be inadequate to induce a high level of immune responses, particularly for people aged 55 years or older, researchers said, suggesting an additional dose given between the third and sixth month after the first as a potential solution.

Participants in the study conducted in Wuhan, China, were found to have adenovirus immunity and were representative of the Chinese adults, the authors acknowledged, adding that such immunity varies globally.

(Reporting by Ankur Banerjee in Bengaluru and Roxanne Liu in Beijing; Editing by Shounak Dasgupta, Nancy Lapid and Bill Berkrot)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.61% 8470 Delayed Quote.11.34%
BIONTECH SE -0.10% 77 Delayed Quote.127.27%
CANSINO BIOLOGICS INC. -4.21% 241 End-of-day quote.308.82%
MODERNA, INC. 0.46% 74.1 Delayed Quote.278.83%
PFIZER LIMITED -0.20% 4382 End-of-day quote.3.74%
PFIZER, INC. 0.47% 38.45 Delayed Quote.-1.86%
share with twitter share with LinkedIn share with facebook
Latest news on CANSINO BIOLOGICS INC.
10:34aCanSino to start Phase III trial of COVID-19 vaccine in Saudi
RE
08/07AstraZeneca Sets Deal in China Market -- WSJ
DJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
08/05Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines
RE
07/30A BIG OBSTACLE : Where can CanSino test its vaccine abroad?
RE
07/30A BIG OBSTACLE : Where can CanSino test its vaccine abroad?
RE
07/29CANSINO BIOLOGICS : Inside information determination of the offer size and issue..
PU
07/26CANSINO BIOLOGICS : Inside information cooperation with pfizer to promote mcv4 p..
PU
07/24WHO scientist sees regulators cooperating to speed COVID-19 vaccine approval
RE
07/23China's Sinopharm says coronavirus vaccine could be ready by year-end - state..
RE
More news
Financials
Sales 2020 122 M 17,5 M 17,5 M
Net income 2020 -109 M -15,6 M -15,6 M
Net Debt 2020 31,6 M 4,54 M 4,54 M
P/E ratio 2020 -350x
Yield 2020 -
Capitalization 48 235 M 6 923 M 6 923 M
EV / Sales 2020 396x
EV / Sales 2021 56,3x
Nbr of Employees 429
Free-Float 44,0%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 156,25 CNY
Last Close Price 216,64 CNY
Spread / Highest target 9,46%
Spread / Average Target -27,9%
Spread / Lowest Target -77,5%
EPS Revisions
Managers
NameTitle
Xue Feng Yu Chairman, Chief Executive Officer & GM
Jiang Feng Li Chairman-Supervisory Board
Shou Bai Chao COO, Executive Director & Deputy General Manager
Jing Wang Chief Financial Officer & Board Secretary
Tao Zhu Executive Director, CSO & Deputy General Manager
Sector and Competitors
1st jan.Capitalization (M$)
CANSINO BIOLOGICS INC.308.82%6 923
CSL LIMITED-0.57%89 334
BIOGEN INC.3.03%48 398
SAMSUNG BIOLOGICS CO.,LTD.77.37%42 742
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.224.31%36 982
WUXI BIOLOGICS (CAYMAN) INC.72.33%29 772